This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Alcon Stock Rises Following the FDA Approval of TRYPTYR
by Zacks Equity Research
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
by Zacks Equity Research
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Abbott Stock Gains Following FDA Approval of the Tendyne System
by Zacks Equity Research
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
BioSig Stock Surges Following Share Exchange Deal With Streamex
by Zacks Equity Research
BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.
PacBio Stock Slips Despite New China Distribution Deal With Haorui
by Zacks Equity Research
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
QGEN Stock Might Gain Following New Partnership With ID Solutions
by Zacks Equity Research
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
by Zacks Equity Research
Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases
Walgreens Opens New Micro-Fulfillment Center in Brooklyn Park
by Zacks Equity Research
WBA expands micro-fulfillment with a new facility in Brooklyn Park, MN. This will support nearly 200 Walgreens stores across the Midwest.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
by Zacks Equity Research
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
by Zacks Equity Research
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
by Zacks Equity Research
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Neogen Stock Gains Following Strategic Alliance With Syngenta
by Zacks Equity Research
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
by Zacks Equity Research
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
by Zacks Equity Research
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
ALGN Stock Might Rise Following the NMPA Approval in China
by Zacks Equity Research
Align Technology receives approval from the National Medical Products Administration in China for its Invisalign Palatal Expander System.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
by Zacks Equity Research
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.